Artikkelit, joihin on yleisen käytön mandaatti - Brady Sillman, PhDLisätietoja
Ei saatavilla missään: 1
Neuropathogenesis of human immunodeficiency virus infection
B Sillman, C Woldstad, J Mcmillan, HE Gendelman
Handbook of clinical neurology 152, 21-40, 2018
Mandaatit: US National Institutes of Health
Saatavilla jossain: 15
Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice
PK Dash, R Kaminski, R Bella, H Su, S Mathews, TM Ahooyi, C Chen, ...
Nature communications 10 (1), 2753, 2019
Mandaatit: US National Institutes of Health
Creation of a long-acting nanoformulated dolutegravir
B Sillman, AN Bade, PK Dash, B Bhargavan, T Kocher, S Mathews, H Su, ...
Nature communications 9 (1), 443, 2018
Mandaatit: US National Institutes of Health
A year-long extended release nanoformulated cabotegravir prodrug
TA Kulkarni, AN Bade, B Sillman, BLD Shetty, MS Wojtkiewicz, N Gautam, ...
Nature materials 19 (8), 910-920, 2020
Mandaatit: US National Institutes of Health
Long-acting slow effective release antiretroviral therapy
B Edagwa, JE McMillan, B Sillman, HE Gendelman
Expert opinion on drug delivery 14 (11), 1281-1291, 2017
Mandaatit: US National Institutes of Health
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs
DP Gnanadhas, PK Dash, B Sillman, AN Bade, Z Lin, DL Palandri, ...
The Journal of clinical investigation 127 (3), 857-873, 2017
Mandaatit: US National Institutes of Health
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
N Gautam, JEM McMillan, D Kumar, AN Bade, Q Pan, TA Kulkarni, W Li, ...
Nature communications 12 (1), 3453, 2021
Mandaatit: US National Institutes of Health
Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques
JE McMillan, A Szlachetka, L Slack, B Sillman, B Lamberty, B Morsey, ...
Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01316-17, 2018
Mandaatit: US National Institutes of Health
CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice
PK Dash, C Chen, R Kaminski, H Su, P Mancuso, B Sillman, C Zhang, ...
Proceedings of the National Academy of Sciences 120 (19), e2217887120, 2023
Mandaatit: US National Institutes of Health
Creation of a long-acting rilpivirine prodrug nanoformulation
JR Hilaire, AN Bade, B Sillman, N Gautam, J Herskovitz, BLD Shetty, ...
Journal of Controlled Release 311, 201-211, 2019
Mandaatit: US National Institutes of Health
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
S Deodhar, B Sillman, AN Bade, SN Avedissian, AT Podany, ...
Nature communications 13 (1), 3226, 2022
Mandaatit: US National Institutes of Health
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
MU Nayan, B Sillman, M Hasan, S Deodhar, S Das, A Sultana, NTH Le, ...
Advanced Drug Delivery Reviews 200, 115009, 2023
Mandaatit: US National Institutes of Health
Recovery of latent HIV-1 from brain tissue by adoptive cell transfer in virally suppressed humanized mice
H Su, S Sravanam, B Sillman, E Waight, E Makarov, S Mathews, ...
Journal of Neuroimmune Pharmacology, 1-10, 2021
Mandaatit: US National Institutes of Health
Polymer delivery systems for long-acting antiretroviral drugs
MU Nayan, S Panja, A Sultana, LA Zaman, LK Vora, B Sillman, ...
Pharmaceutics 16 (2), 183, 2024
Mandaatit: US National Institutes of Health
Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model
EG Foster, B Sillman, Y Liu, M Summerlin, V Kumar, BR Sajja, ...
Frontiers in Pharmacology 14, 1294579, 2023
Mandaatit: US National Institutes of Health
Pathways for dolutegravir transformation from a daily oral to a once-a-year parenteral medicine
S Deodhar, B Sillman, A Bade, JE McMillan, N Gautam, B Hanson, ...
Mandaatit: US National Institutes of Health
Tietokoneohjelma arvioi ja määrittää julkaisu- ja rahoitustiedot automaattisesti